Repare Therapeutics (NASDAQ: RPTX) unveiled its Q4 earnings on February 28, 2024, revealing an EPS of $-0.67, falling short of the expected EPS of $-0.46 by -46.0%. Revenue also took a hit, decreasing by $5.15 million compared to the same period last year.
In the previous quarter, Repare Therapeutics surpassed EPS projections by $0.41, resulting in a 5.0% surge in share price the following day.
For a more comprehensive look at Repare Therapeutics’ historical performance:
– Q3 2023: Estimated EPS -0.86, actual EPS -0.45, revenue estimate 6.31M, actual revenue 2.16M.
– Q2 2023: Estimated EPS -0.78, actual EPS -0.28, revenue estimate 7.68M, actual revenue 30.25M.
– Q1 2023: Estimated EPS -0.81, actual EPS -0.83, revenue estimate 6.12M, actual revenue 5.68M.
– Q4 2022: Estimated EPS -0.97, actual EPS -0.75, revenue estimate 10.83M, actual revenue 18.20M.
Repare Therapeutics recently shared a business update alongside its Q4 and full year 2023 financial results. The company is poised to reclaim global development and commercialization rights in May 2024. For more information or to listen to the earnings call directly, please visit Repare Therapeutics’ investor relations page.
Repare Therapeutics Inc. (RPTX) Stock Sees Modest Increase on February 28, 2024: What Investors Should Know
On February 28, 2024, Repare Therapeutics Inc. (RPTX) saw a modest increase in its stock performance. The stock opened at $6.66, which was $0.04 higher than its previous close. Throughout the trading day, RPTX experienced a price increase of $0.04, resulting in a 0.60% rise in its share price. Investors may want to consider these factors when evaluating RPTX as a potential investment. Keeping an eye on RPTX’s performance in the coming days and weeks may provide additional insights into the stock’s trajectory and potential for future growth.
RPTX Stock Analysis: Fluctuations in Financial Performance on February 28, 2024
On February 28, 2024, RPTX stock experienced significant fluctuations in its financial performance compared to the previous year and quarter. According to data from CNN Money, the total revenue for RPTX stood at $131.83 million over the past year, representing an increase of 1634.61% from the previous year. However, the total revenue for the most recent quarter was reported at $2.16 million, indicating a decrease of 92.86% from the previous quarter.
The net income for RPTX was reported at -$29.05 million over the past year, showing an increase of 72.83% from the previous year. However, the net income for the most recent quarter was reported at -$18.88 million, reflecting a decrease of 58.04% from the previous quarter.
The earnings per share (EPS) for RPTX was reported at -$0.69 over the past year, showing an increase of 75.49% from the previous year. However, the EPS for the most recent quarter was reported at -$0.45, indicating a decrease of 58.0% from the previous quarter.
Overall, the financial performance of RPTX on February 28, 2024, showed a mix of positive and negative trends. Investors and analysts will likely be closely monitoring RPTX stock to see how the company navigates these fluctuations in its financial performance in the coming quarters.
